Bibliography
- Katlama C, Haubrich R, Lalezari J, Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300
- Madruga JV, Cahn P, Grinsztejn B, Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38
- Lazzarin A, Campbell T, Clotet B, Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48
- Hammer SM, Eron JJ Jr, Reiss P, Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-70
- Lazzarin A, Clotet B, Cooper D, Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95
- Steigbigel RT, Cooper DA, Kumar PN, Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
- Gulick RM, Lalezari J, Goodrich J, Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
- Katlama C, Esposito R, Gatell JM, Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395-402
- Clotet B, Bellos N, Molina JM, Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78
- De Meyer S, Azijn H, Surleraux D, TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314-21
- Andries K, Azijn H, Thielemans T, TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6
- Vingerhoets J, Tambuyzer L, Azijn H, Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24(4):503-14
- Ledergerber B, Lundgren JD, Walker AS, Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62
- Recsky MA, Brumme ZL, Chan KJ, Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis 2004;190:285-92
- Montaner JS, Harrigan PR, Jahnke N, Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001;15:61-9
- Nelson M, Arasteh K, Clotet B, Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-12
- Yazdanpanah Y, Fagard C, Descamps D, High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49:1441-9